title: Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.
abstract: Importance. Medication-induced eosinophilia is an acknowledged, often self-limiting occurrence. Glatiramer acetate, a biologic injection used in the management of relapsing-remitting multiple sclerosis, is widely regarded as a safe and effective medication and lists eosinophilia as an infrequent side effect in its package insert. Contrary to reports of transient, benign drug-induced eosinophilia, we describe a case of probable glatiramer acetate-induced eosinophilia that ultimately culminated in respiratory distress, shock, and eosinophilic myocarditis. Observations. A 59-year-old female was admitted to the hospital after routine outpatient labs revealed leukocytosis (43,000 cells/mm(3)) with pronounced hypereosinophilia (63%). This patient had been using glatiramer acetate without complication for over 10 years prior to admission. Leukocytosis and hypereosinophilia persisted as a myriad of diagnostic evaluations returned negative, ultimately leading to respiratory depression, shock, and myocarditis. Glatiramer acetate was held for the first time on day 6 of the hospital stay with subsequent resolution of leukocytosis, hypereosinophilia, respiratory distress, and shock. Conclusions and Relevance. Glatiramer acetate was probably the cause of this observed hypereosinophilia and the resulting complications. Reports of glatiramer-induced eosinophilia are rare, and few case reports regarding medication-induced hypereosinophilia describe the severe systemic manifestations seen in this patient.
authors.affiliation: Department of Pharmacy, Spectrum Health, 100 Michigan Street NE, MC 001, Grand Rapids, MI 49503, USA.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Michaud
authors.affiliation: Department of Pharmacy, Spectrum Health, 100 Michigan Street NE, MC 001, Grand Rapids, MI 49503, USA.
authors.forename: Heather M
authors.initials: HM
authors.lastname: Bockheim
authors.affiliation: Internal Medicine, Spectrum Health, Grand Rapids, MI 49503, USA.
authors.forename: Muhammad
authors.identifier: 0000-0003-3225-3099
authors.initials: M
authors.lastname: Nabeel
authors.affiliation: Pulmonary Critical Care, Spectrum Health Medical Group, Grand Rapids, MI 49503, USA.
authors.forename: Timothy E
authors.initials: TE
authors.lastname: Daum
references.citation: Cochrane Database Syst Rev. 2010 May 12;(5):CD004678
references.pmid: 20464733
references.citation: CNS Drugs. 2011 Jan;25(1):67-88
references.pmid: 21128695
references.citation: Neurology. 2007 Mar 20;68(12):939-44
references.pmid: 17372130
references.citation: N Engl J Med. 2010 Feb 4;362(5):402-15
references.pmid: 20089954
references.citation: Clin Exp Dermatol. 2011 Jan;36(1):6-11
references.pmid: 21143513
references.citation: Acta Neurol Belg. 2005 Jun;105(2):81-5
references.pmid: 16076061
references.citation: Toxicol Pathol. 2012;40(1):40-54
references.pmid: 22083585
references.citation: Ann Neurol. 2013 Jun;73(6):705-13
references.pmid: 23686821
references.citation: Ann Neurol. 2007 Jan;61(1):14-24
references.pmid: 17262850
references.citation: Nat Rev Neurol. 2011 May;7(5):255-62
references.pmid: 21467994
references.citation: Neurology. 1998 Mar;50(3):701-8
references.pmid: 9521260
references.citation: Clin Pharmacol Ther. 1981 Aug;30(2):239-45
references.pmid: 7249508
references.citation: Arch Dermatol. 2001 Mar;137(3):357-64
references.pmid: 11255340
references.citation: N Engl J Med. 1987 Aug 13;317(7):408-14
references.pmid: 3302705
references.citation: Am J Med. 2011 Jul;124(7):588-97
references.pmid: 21592453
references.citation: Ann Neurol. 2001 Mar;49(3):290-7
references.pmid: 11261502